(1132-A) Assessing microenvironment recapitulation of a 3D printed ovarian-tumoroid-on-a-chip via PARP inhibitor treatment response
Monday, February 5, 2024
12:00 PM – 1:00 PM EST
Location: Exhibit Halls AB
Abstract: The most lethal form of gynecological cancer, ovarian cancer deaths in the United States numbered 13,940 in 2020 alone, accounting for approximately 41.46% of that year’s gynecological cancer deaths. Though there exist a few therapeutic treatments for the condition, current testing methods for such drugs are primarily centered on examining patient outcomes over a given number of years. The timeline often spans many years and limits researchers to working with a lower sample size to determine the efficacy of the drug. As such, there exists a clinical need for a more rapid, scalable method for testing ovarian cancer drugs. Tumor-on-a-chip (TOC) models have recently garnered attention as a reliable platform for testing ovarian cancer drugs. However, limitations still exist in the form of the assay's manufacturing scalability, as well as accuracy in the flow pattern of the drug to the organoid/tumorid. Our study uses a UV-cured 3D-printed TOC device, with a laser-cut plastic gasket for flow control, using Olaparib delivery to the CaOV3 cell line as a cell-viability measure. We use an in-house LC-MS/MS assay for both Olaparib quantification from cell culture media and measuring pre- and post circulation drug quantity from the tumoroid microenvironment. The goal of this study is to showcase a rather simplistic strategy to scale up TOC technology, and has the potential for application in personalized medicine in the future.